According to The Insight Partners' research, the Asia Pacific Point of Care Diagnostics Market was valued at US$ 8,521.7 Million in 2024 and is expected to reach US$ 22,950.4 Million by 2031, registering a CAGR of 15.3% from 2025 to 2031.
Key product launches and developments and increasing prevalence of infectious diseasesare among the critical factors attributed to driving the Asia Pacific point of care diagnostics market growth.
The number of point-of-care tests has increased since its introduction. It is expected to grow with new product launches intended at delivering inexpensive care at the facilities at the closest possible distance from the patients' location. New products or technologies are being introduced to enhance the effectiveness of devices with incremental improvements in analytical performance. The growth of the point of care diagnostics market is mainly driven by the introduction of new devices to perform molecular tests. New devices launched in the recent years include:
- In January 2023, Cipla Limited launched Cippoint, a point-of-care testing device. This state-of-the-art device provides testing parameters such as cardiac markers, infectious diseases, diabetes, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers. The device is CE IVD approved - indicating that the device is approved by the European In-Vitro Diagnostic Device Directive, providing reliable testing solutions.
The point-of-care diagnostics market is witnessing rapid growth, driven by continuous innovation and the introduction of advanced testing technologies. These developments focus on enhancing accessibility, affordability, and speed of diagnosis, especially for critical and infectious conditions. The trend toward decentralization supports early intervention and better disease management. As diagnostic tools become increasingly portable and precise, their impact on healthcare delivery continues to grow stronger.
On the contrary, the product recalls hamper the growth of the Asia Pacific point of care diagnostics market.
Asia Pacific Point of Care Diagnostics Market Segmentation Analysis:
- By Product, the Asia Pacific Point of Care Diagnostics Market is segmented into Glucose Monitoring, Infectious Disease Testing, Cardio metabolic Testing, Pregnancy And Fertility Testing, Coagulation Testing, Tumor or Cancer Marker Testing, Cholesterol Testing, Urinalysis Testing, Hematology Testing, Thyroid Testing, and Others. The Glucose Monitoring segment is projected to expand at 18.3% CAGR during 2025 - 2031.
- By Glucose Monitoring, the Asia Pacific Point of Care Diagnostics Market is segmented into Blood Glucose Meter, Lancet, and Strips. The Strips segment is projected to expand at 17.8% CAGR during 2025 - 2031.
- By Infectious Disease Testing, the Asia Pacific Point of Care Diagnostics Market is segmented into HIV Testing, Influenza Testing, Sexually Transmitted Diseases Testing, Hepatitis C Virus Testing, Tropical Diseases Testing, Respiratory Infection Testing, Hospital Acquired Infections, and Others. The Respiratory Infection Testing segment is projected to expand at 19.2% CAGR during 2025 - 2031.
- By Cardio Metabolic Testing, the Asia Pacific Point of Care Diagnostics Market is segmented into Cardiac Troponin (cTn) Test, Myoglobin Test, and Others. The Cardiac Troponin (cTn) Test segment is projected to expand at 15.5% CAGR during 2025 - 2031.
- By Purchase Mode, the Asia Pacific Point of Care Diagnostics Market is segmented into OTC and Prescription. The Prescription segment is projected to expand at 14.9% CAGR during 2025 - 2031.
- By Sample, the Asia Pacific Point of Care Diagnostics Market is segmented into Blood, Urine, and Others. The Blood segment is projected to expand at 15.7% CAGR during 2025 - 2031.
- By End User, the Asia Pacific Point of Care Diagnostics Market is segmented into Healthcare Facilities, Homecare, and Others. The Healthcare Facilities segment is projected to expand at 15.4% CAGR during 2025 - 2031.
- By Healthcare Facilities, the Asia Pacific Point of Care Diagnostics Market is segmented into Hospitals and Clinics, Diagnostic Centers, and Others. The Diagnostic Centers segment is projected to expand at 15.7% CAGR during 2025 - 2031.
By country, the Asia Pacific Point of Care Diagnostics Market is categorized into China, Japan, India, Australia, South Korea, and the Rest of APAC. Japan is projected to expand at 15.5% CAGR during 2025 - 2031.
Key players operating in the Point of Care Diagnostics Market are Siemens AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, bioMerieux SA, Bio-Rad Laboratories Inc, QIAGEN NV, Nova Biomedical Corporation, Polymer Technology Systems, Inc. (PTS), and Danaher Corp, among others.
- In February 2025, bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE FILMARRAY Gastrointestinal (GI) Panel Mid has obtained clearance from the U.S. Food and Drug Administration (FDA). This midplex molecular panel tests for 11 of the most common bacteria, viruses, and parasites associated with gastroenteritis - all from one sample, with results available in approximately one hour.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com